Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study is to determine that pembrolizumab is safe and tolerable at the selected dose for
the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with a performance status of
2. All patients will receive pembrolizumab.